Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials
about
Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)-multiple rather than a single mechanismCustomized targeted therapy in Hodgkin lymphoma: hype or hope?Next-generation surveillance strategies for patients with lymphomaHodgkin lymphoma, version 2.2015.The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialLong-term Toxicity of Cancer Treatment in Older PatientsSecond malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis.Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia.Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.Therapy-related myelodysplasia and acute myeloid leukemiaTherapy-related myelodysplastic syndrome.Novel agents for the treatment of Hodgkin lymphoma.Risk-adapted strategies for the treatment of Hodgkin lymphoma.Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience.Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.Multiple primary tumors following stage II and III rectal cancer in patients receiving radiotherapy, 1998-2010.Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.Synchronous Hodgkin lymphoma and gastric adenocarcinoma: A rare case report and literature review.Different clones of acute leukemia after successful treatment of Hodgkin's disease.
P2860
Q26830271-E6CDADDC-4E2E-442A-BAB4-F397A5EFA79AQ27002554-D326817C-C23D-4A3D-85DC-18B402D91DA8Q28084956-9D64D9FC-7735-4DE2-AFEE-ACCC7A5F611FQ30769157-F10D2C9E-4176-40A6-8949-ED5853FCF278Q35091669-5D6ED2B8-C51D-4049-A6AF-745DDAEC6437Q35671369-1B0C3D18-D8E4-4ABD-8D2B-B8C2E75000CCQ36821673-DC5F2366-3F41-477C-9ADF-221F0FC90E39Q36936841-6CEEFE1B-694A-4C9D-87BC-B580C2DB44DFQ37002149-EB47173D-E9EA-440D-83C7-D047672B74E0Q37216339-9663BE65-EE69-4523-81DE-AEFFC1738651Q37402657-8D936280-7FA6-4B0E-BD1C-6038E62C2299Q38353167-97D625E8-F52B-4DFE-B80F-F1C9AADCD299Q38581830-AC9F069D-AAA2-4C83-B41C-6E51DBA8577BQ38591137-32257573-33F1-4512-A3B0-EF6ECE600802Q38775871-5E316348-C07B-4F6D-B7E5-5F3C3BADF687Q38860992-9DE74112-0871-44DF-BFDE-451C819185FEQ38881049-C291E8F6-6331-4A33-95C3-4CEFF9B66306Q40040274-9258C3EC-9FCA-4D05-B60E-789F0D4C30F9Q40044179-C524E02C-DB73-4958-8A94-C5F1B74288BDQ40239182-C5531811-20DA-42B3-9FFC-B8D2CE9F94BEQ41632376-3B68646A-F7F9-458A-9F84-D80B562F978AQ44457114-AB8BA8D7-766F-449E-830A-0297C8406DA7Q44512399-436D58A7-BEBA-414C-B5D2-0D9F44BB0621Q46192794-83B45EDB-EC0D-46E4-8F77-B5DC7D9F206FQ48346165-280D4C43-6674-4952-BC4E-CB7780D051A9Q49636510-AAB3BAAE-0F5F-4DBB-B9D6-0CCB7E9E0232Q54354801-62E6E1C3-4DDC-4200-BC8C-4270DFF72AE0
P2860
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Risk of therapy-related second ...... generations of clinical trials
@ast
Risk of therapy-related second ...... generations of clinical trials
@en
type
label
Risk of therapy-related second ...... generations of clinical trials
@ast
Risk of therapy-related second ...... generations of clinical trials
@en
prefLabel
Risk of therapy-related second ...... generations of clinical trials
@ast
Risk of therapy-related second ...... generations of clinical trials
@en
P2093
P2860
P356
P1476
Risk of therapy-related second ...... generations of clinical trials
@en
P2093
Michael Zach Koontz
Peter L Greenberg
Ranjana H Advani
Raymond Balise
Richard T Hoppe
Sandra J Horning
Saul A Rosenberg
P2860
P304
P356
10.1200/JCO.2012.44.5791
P407
P577
2013-01-07T00:00:00Z